Learn how demographic and behavioral insights inform platform-specific messaging, creative formats, and call-to-action ...

In today’s ACT Brief, we look at how Trialbee evaluates nontraditional digital platforms for patient recruitment, review new 48-week data from J&J’s APEX trial of Tremfya in psoriatic arthritis, and ...

New 48-week results from Johnson & Johnson’s Phase IIIb APEX trial show Tremfya delivers durable symptom improvement, slows radiographic progression, and maintains a consistent safety profile in ...

Explore which factors—audience relevance, content fit, and engagement quality—determine the best use of platforms like TikTok ...

In today’s ACT Brief, we look at how real-world data and AI are helping prevent costly study rescue, review the FDA’s ...

ACT: At this year’s SCRS Summit, several site representatives raised concerns about overly complex protocols and patient ...

How sponsors can leverage technology to enhance, not hinder, site efficiency and usability Strategies to incorporate site ...

In today’s ACT Brief, we look at how artificial intelligence is reshaping drug development decisions across pharma, discuss ...

Data-driven planning aids in the design of feasible clinical trials from the outset, by simulating enrollment before the ...

Gain insight into how principal investigator scarcity, frequent protocol amendments, and uneven site performance undermine ...

In today’s ACT Brief, we examine declining site satisfaction and strategies to improve sponsor-site collaboration, review a ...

Understand how combining proprietary and real-world datasets with tokenization enables accurate protocol matching while ...